Symbolbild · KI-generiert
DBV Technologies S.A.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
DBV Technologies is a French biotechnology company developing transdermal immunotherapies based on its Viaskin patch technology. The primary focus is on treating food allergies, particularly peanut allergy in children.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| DBV Technologies S.A. | DBVT | NASDAQ | 799 Mio. USD |
| Kura Oncology, Inc. | KURA | NASDAQ | 800 Mio. USD |
| SS Innovations International Inc. | SSII | NASDAQ | 797 Mio. USD |
| Solid Biosciences Inc. | SLDB | NASDAQ | 794 Mio. USD |
| SI-BONE, Inc. | SIBN | NASDAQ | 788 Mio. USD |
| CCL Industries Inc. Unlimited Class A Voting Shares | CCL.A | TSX | 774 Mio. USD |
| Geron Corporation | GERN | NASDAQ | 828 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.